Low-dose paclitaxel prior to intratumoral dendritic cell vaccine modulates intratumoral cytokine network and lung cancer growth.
about
First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activityImmunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapyChemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanismNovel multiarm polyethylene glycol-dihydroartemisinin conjugates enhancing therapeutic efficacy in non-small-cell lung cancer.Clinical effects of autologous dendritic cells combined with cytokine-induced killer cells followed by chemotherapy in treating patients with advanced colorectal cancer: a prospective study.Multiplexed microbead immunoassays by flow cytometry for molecular profiling: Basic concepts and proteomics applications.The role of Bcl-xL and nuclear factor-kappaB in the effect of taxol on the viability of dendritic cellsPaclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in miceChemoimmunotherapy.Interstitial fluid: the overlooked component of the tumor microenvironment?Epothilone B enhances surface EpCAM expression in ovarian cancer Hey cellsChemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanismsSpecific microtubule-depolymerizing agents augment efficacy of dendritic cell-based cancer vaccines.Low-dose paclitaxel improves the therapeutic efficacy of recombinant adenovirus encoding CCL21 chemokine against murine cancer.Post-chemotherapy T-cell recovery is a marker of improved survival in patients with advanced thoracic malignancies.Intratumoral chemotherapy for lung cancer: re-challenge current targeted therapies.In vivo amelioration of endogenous antitumor autoantibodies via low-dose P4N through the LTA4H/activin A/BAFF pathway.Exploitation of the propulsive force of chemotherapy for improving the response to cancer immunotherapy.Immune modulation by chemotherapy or immunotherapy to enhance cancer vaccines.Paclitaxel nanoparticle awakens immune system to fight against cancer.Combination strategies to enhance the potency of monocyte-derived dendritic cell-based cancer vaccines.Low-dose chemotherapeutic agents regulate small Rho GTPase activity in dendritic cells.Comparison of microdialysis sampling perfusion fluid components on the foreign body reaction in rat subcutaneous tissue.Anticancer and immunostimulatory activity by conjugate of paclitaxel and non-toxic derivative of LPS for combined chemo-immunotherapy.Low-dose paclitaxel enhances the anti-tumor efficacy of GM-CSF surface-modified whole-tumor-cell vaccine in mouse model of prostate cancer.Preconditioning chemotherapy with paclitaxel and cisplatin enhances the antitumor activity of cytokine induced-killer cells in a murine lung carcinoma model.Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrationsDendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer.Therapeutic response in patients with advanced malignancies treated with combined dendritic cell-activated T cell based immunotherapy and intensity-modulated radiotherapyImmunological Mechanisms of Low and Ultra-Low Dose Cancer Chemotherapy.Enhancing immunotherapy using chemotherapy and radiation to modify the tumor microenvironment.Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model.The role of TLR4 in the paclitaxel effects on neuronal growth in vitro.Overcoming immunosuppression in the melanoma microenvironment induced by chronic inflammation.Autologous cytokine-induced killer cell immunotherapy may improve overall survival in advanced malignant melanoma patients.Microneedle-Assisted, DC-Targeted Codelivery of pTRP-2 and Adjuvant of Paclitaxel for Transcutaneous Immunotherapy.Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy.Efficacy of granulocyte-macrophage colony-stimulating factor combined with metronomic paclitaxel in the treatment of Lewis lung carcinoma transplanted in mice.[Paclitaxel blocks immunologic escape through up-regulating TAP-1, TAP-2 and eliminatiing Treg cells in 3LL-bearing mice].Paclitaxel inhibits killing by murine cytotoxic T lymphocytes in vivo but not in vitro.
P2860
Q21245463-CB8EAFD9-62C5-4158-BA59-43BC9F9DC3F1Q27027093-58EAF72C-DA12-472C-902B-C8BB2331C7DEQ28384980-8A2D58BA-0A64-4F34-85FA-45A16791ED8AQ30359589-280DC30A-CF3D-4149-BFCA-04B00B1EAF97Q33427019-EE6477BE-4655-425E-AFA1-CB61A206917AQ33465218-A40C6409-62D7-4440-90AA-01D20DE1231FQ33569063-E8F4003A-C3A6-42B5-AC3D-FA25801ABC4DQ33823499-B14372FC-DCF7-473F-BF64-4F3CA71EB1B5Q34058792-3C68B2F2-776A-4ABA-A71F-3725771DDF2DQ34060641-6B2A5003-82EB-4281-9B32-765F25000DDCQ34188631-2CC89680-21F7-48F3-9D30-768029A9FBB0Q34343736-82E7F5BD-9375-4BDE-9F50-9122A5E6064CQ35122102-7E6724E6-D6A7-4357-A1F2-CAD286775954Q35713347-F1B8203E-AB37-4FD4-8383-EBB711C0162BQ36287976-EBA35F91-18E2-4C99-9C4E-2D6606DF97C0Q37033793-D0FA1747-CD80-4376-9089-E90918E3208DQ37474087-0A72DD75-B382-4599-84C5-E18E7BBDCB8FQ37969356-7DE1266F-E4B7-47BF-AFE2-C081590FEE9DQ38161367-A8DDBBC2-6C0C-49CE-A077-6BBE7232D408Q38688207-EA406D98-6D36-4CA8-B900-E6B164856C93Q38948897-A9326CB5-6435-472E-ACAC-7F2F60AF3AE7Q39000198-2738B9FC-FCB4-43AF-9347-364C6C7034E1Q39062311-48F202FC-C1AD-45CA-9055-97699809B6D8Q39356108-EB0C543C-45B8-43CE-955A-A27439208103Q39589931-9E3A7669-8EC9-4A4F-ACCE-F762CBFF9AD0Q39650152-17811EFD-FE5A-40A9-98C5-A5ABA7081E24Q39826691-99FFB7E3-EDEA-4C0B-9720-4EB8D6F71BD5Q40321426-8B0D8AA9-616C-4E4D-8418-F331DC79B61EQ42093293-D8C6FC80-A274-4A23-8F7D-DF7FF5A52535Q42701148-BA6A3217-D0AF-40D9-A018-2D1F0488887DQ42848419-60E05FCA-BA0E-4F49-B89F-249EF82EB00CQ43243177-11BA5CE6-E85B-474C-81A0-0877BF7D266AQ43245268-72E84BDC-C259-40A8-ABED-522824250FE4Q46897065-9E78B691-AF4F-4AF6-B476-3B11F23AEE3CQ47733182-AE3C4BD6-1D2C-4F99-B870-2B8FBDF6576DQ48351402-0F05451C-A2EE-4AD8-B964-C33C49F14660Q48535444-7312F612-3AFA-4145-8579-180AD1C75768Q50045837-D4708999-0AD0-4AFD-ABF2-A6717FA3E6E0Q53294709-13BC6801-08F0-4DB3-B2B2-0C529A76B90EQ53355475-D0573AD1-56FC-4D89-9B3D-55E7157535C7
P2860
Low-dose paclitaxel prior to intratumoral dendritic cell vaccine modulates intratumoral cytokine network and lung cancer growth.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Low-dose paclitaxel prior to i ...... etwork and lung cancer growth.
@en
type
label
Low-dose paclitaxel prior to i ...... etwork and lung cancer growth.
@en
prefLabel
Low-dose paclitaxel prior to i ...... etwork and lung cancer growth.
@en
P2093
P2860
P1476
Low-dose paclitaxel prior to i ...... etwork and lung cancer growth.
@en
P2093
Alan Rosenbloom
Anna Lokshin
Baohui Han
Galina V Shurin
Irina L Tourkova
Michael R Shurin
P2860
P304
P356
10.1158/1078-0432.CCR-07-0517
P407
P433
P577
2007-09-01T00:00:00Z